Mesoblast soars following FDA advisory panel vote in favor of remestemcel-L Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Mesoblast (MESO) up 47% after announcing that the Oncologic Drugs Advisory Committee of the FDA voted nine to one in favor that the available data support the efficacy of remestemcel-L in pediatric patients with steroid-refractory acute graft versus host disease
- Novavax (NVAX) up 7% after announcing it has signed a term sheet with the Government of the United Kingdom for the purchase of 60M doses of NVX-CoV2373, the company's COVID-19 vaccine and a Phase 3 clinical trial to assess the efficacy of the vaccine in the UK population
- Tesla (TSLA) up 2% after BofA analyst John Murphy upgraded shares to Neutral from Underperform and Morgan Stanley's Adam Jonas raised his rating on the stock to Equal Weight from Underweight
UP AFTER EARNINGS -
- Soligenix (SNGX) up 1%
- Bio-Path Holdings (BPTH) up 2%
- ContraFect (CFRX) up 1%
- Applied Materials (AMAT) up 3%
DOWN AFTER EARNINGS -
- DraftKings (DKNG) down 7%
- BioXcel Therapeutics (BTAI) down 5%
- Baidu (BIDU) down 5%
- Ocugen (OCGN) down 12%
ALSO LOWER -
- iQIYI (IQ) down 5% after reporting a SEC investigation into its financial records
- KE Holdings (BEKE) down 9% after its stock began trading yesterday following the company's IPO
Symbols:
MESO NVAX TSLA - $1,620.60 /
+65.9 (+4.24%)
SNGX BPTH CFRX AMAT DKNG BTAI BIDU - $124.65 /
-1.425 (-1.13%)
OCGN IQ BEKE Keywords: Fly Intel, Wall Street, Top Stories, Stocks